MG
RNA

Michael Gelband’s Atrium Therapeutics RNA Stock Holding History

Michael Gelband’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Buy
117,275
+39,833
+51% +$520K 0.01% 919
2026
Q1 		$1.04M Buy
+77,442
New +$1.09M 0.01% 988

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Michael Gelband's RNA Position: Q2 2026 in Review

Michael Gelband increased its Atrium Therapeutics (RNA) stake by 51% in Q2 2026, buying an estimated $520K and bringing the position to 117,275 shares worth $1.58M. The position accounts for 0.01% of the portfolio, ranked #919.

Michael Gelband first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 153 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Michael Gelband held 117,275 shares of Atrium Therapeutics worth $1.58M as of Q2 2026.
  • Michael Gelband bought 39,833 Atrium Therapeutics shares in Q2 2026, an estimated $520K.
  • Atrium Therapeutics made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #919 holding.
  • Michael Gelband first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 153 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.